Thursday Jul 24
CardioDX raises $21M in new funding as biotech IPOs hit rough patch
CardioDX, led by David Levison, has raised $21 million of a planned $25 million in new private funding.
CardioDx Announces Aetna and Coventry Health Coverage for Corus(R) CAD Gene Expression Test
With this decision, the Corus CAD gene expression test is eligible for coverage among Aetna and Coventry Health members.
Kleiner Perkins, Domain lead VC pack emerging from biotech IPOs
Brook Byers leads Kleiner Perkins Caufield. Byers' investments in CardioDx and CareDx - two molecular diagnostics companies in the Bay Area with outstanding IPOs - and Veracyte, a member of the IPO Class of 2013.